



I FW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/743,613
Filing Date	December 22, 2003
First Named Inventor	Paul Spurr
Art Unit	1614
Examiner Name	
Total Number of Pages in This Submission	21436 US

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
<p><b>-RESUBMISSION - of IDS sent 3/22/04</b></p> <p><b>-Refs. B1 to B18, and C1 to C17; and</b></p> <p><b>-Copy of co-pending, co-owned USSN.</b></p> <p><b>10/322,272 (CD 20661 US2); and</b></p> <p><b>10/310,508 (CD 20661 US1)</b></p>		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Kimberly J. Prior
Signature	
Date	May 20, 2004

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Kimberly J. Prior
Signature	
Date	May 20, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor: Paul Spurr

Group: 1614

Serial No. 10/743,613, filed December 22, 2003  
(Ref. No. 21436 US)

For: **CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES**

**RESUBMISSION OF INFORMATION DISCLOSURE STATEMENT**  
**SUBMITTED MARCH 22, 2004**

Nutley, New Jersey 07110  
May 20, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The following Information Disclosure Statement is a **resubmission** of an Information Disclosure Statement submitted to the United States Patent and Trademark Office ("USPTO") on March 22, 2004. The USPTO database does not indicate receipt of the original submission of the Information Disclosure Statement and Acknowledgement card submitted on March 22, 2004.

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1 to B18, and C1 to C17 listed on Form PTO-1449 are enclosed. Documents A1 to A4 are not being submitted as they are US Patents.

Serial No. 10/743,613  
Filed: December 22, 2003


Documents B3, B9, and B12, which are not written in the English language, are abstracted in Documents C3, C16, and C17, respectively. Documents B4 and B6, which are not written in the English language, correspond to Documents A1 and A2, respectively.

The Examiner's attention is also directed to co-pending, co-owned US patent applications Serial No. 10/310,508, filed December 5, 2002 (Case Docket No. 20661 US1), and Serial No. 10/322,272, filed December 18, 2002 (Case Docket No. 20661 US2), copies of which are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,



Attorney for Applicant(s)  
Kimberly J. Prior  
(Reg. No. 41,483)  
340 Kingsland Street  
Nutley, New Jersey 07110  
Telephone: (973) 235-6208  
Telefax: (973) 235-2363

Enclosures

142507

MAY 24 2004

JC53

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

## Complete if Known

Application Number	10/743,613
Filing Date	December 22, 2003
First Name Inventor	Paul Spurr
Art Unit:	1614

Sheet	1	of	2	Attorney Docket Number	21436 US
-------	---	----	---	------------------------	----------

## U.S. PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	A1	5,099,021		Worther et al	03/24/1992
	A2	3,725,428		Janiak, S.	04/03/1973
	A3	4,028,374		Pelosi, Jr. et al.	06/07/1977
	A4	6,521,754		Alanine, et al.	02/18/2003

## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	B1	WO	01/97786		F.Hoffmann-La Roche AG	12/27/2001	
	B2	EP	0 282 971		Warner Lambert Co.	09/21/1988	
	B3	EP	0 529 600		Hoechst Aktiengesellschaft	03/03/1993	
	B4	EP	0 427 963		Worther et al	05/22/1991	
	B5	EP	0 295 656		Abe, S. et al	12/21/1988	
	B6	DE	1953149		Ciba AG	05/06/1970	
	B7	WO	00/18767		He, X. et al	04/06/2000	
	B8	GB	1 345 552A		Societe Nationale De Petroles D'Aquitaine	01/30/1974	
	B9	FR	2 753 970 a		Synethelabo	04/03/1998	
	B10	EP	0199400A		Jansen Pharmaceuticals	10/29/1986	
	B11	GB	1 538 822A		Boehringer Mannheim	01/24/1979	
	B12	WO	00/27819A		Novartis AG	05/18/2000	
	B13	EP	0 404 440		Pfizer Inc.	12/27/1990	
	B14	EP	0 604 657		Otsuka Pharma Co.	07/06/1994	
	B15	EP	0 343 893		Pfizer Inc.	11/29/1989	
	B16	WO	99/24035		Squibb Bristol Myers	05/10/1999	
	B17	WO	01/19360a2		Can-Fite Technologies	09/08/2000	
	B18	WO	99/37630		Versicor Inc.	01/22/1990	
Examiner Signature		Date Considered					

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)				<b>Complete if Known</b>	
Sheet 2 of 2		Application Number		10/743,613	
		Filing Date		December 22, 2003	
		First Name Inventor		Paul Spurr	
		Art Unit:		1614	
		Attorney Docket Number		21436 US	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			<sup>2</sup>
	<b>C1</b>	Forlani, L. et al., <i>J. Heterocyclic. Chem.</i> Vol. 37, 2000 pgs. 63-69			
	<b>C2</b>	McDonald, F. et al., <i>Synthesis</i> 2000, No. 7, pgs. 970-974			
	<b>C3</b>	Abstract corresponding to EP 0 529 600 (Document B3)			
	<b>C4</b>	Colotta, V. et al., <i>Arch. Pharm. Med. Chem.</i> , 332 (1999) pgs. 39-41			
	<b>C5</b>	Baraldi, P. G. et al., <i>J. Med. Chem.</i> , 39 (1996) pgs. 1164-1171			
	<b>C6</b>	Li, A. H. et al., <i>J. Med. Chem.</i> , 42 (1999) pgs. 706-721			
	<b>C7</b>	Kim, Y. C. et al., <i>J. Med. Chem.</i> , 41 (1998) pgs. 2835-2845			
	<b>C8</b>	Li, A. H. et al., <i>J. Med. Chem.</i> , 41 (1998) pgs. 3186-3201			
	<b>C9</b>	Baraldi, P. G. et al., <i>J. Med. Chem.</i> , 41 (1998) pgs. 2126-2133			
	<b>C10</b>	Poulsen, S. A. et al., <i>Bioorganic &amp; Medicinal Chemistry</i> , 6 (1998) pgs. 619-641			
	<b>C11</b>	Müller, C. E. et al., <i>Bioorganic &amp; Medicinal Chemistry</i> , 6 (1998) pgs. 707-719			
	<b>C12</b>	Patent Abstracts of Japan, Vol. 1999, No. 10, JP 11 130761a			
	<b>C13</b>	Pandeya, Surendra N. et al., <i>Indian Drugs</i> (1985), 23(3), 146-51 XP0080000199			
	<b>C14</b>	Daidone, G. et al., Vol. 44, No. 5 (1989), pgs. 465-473, XP001053114			
	<b>C15</b>	The Merck Index 12 <sup>th</sup> Ed. (1996) p. 506			
	<b>C16</b>	Abstract corresponding to FR 2 753 970 (Document B9)			
	<b>C17</b>	Abstract corresponding to WO 00/27819 (Document B12)			
Examiner Signature		DATE CONSIDERED			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

140357